Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
Condition: Psoriasis
MeSH terms: Psoriasis
Intervention: Desoximetasone Spray 0.25%; placebo comparator
Intervention description: Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days; Placebo administered to affected area twice a day for 28 days
Intervention MeSH terms: Desoximetasone
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Enrollment: 120.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      efficacy study in patients with moderate to severe plaque psoriasis.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating female 18 years of age or older.

          -  Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the
             body surface area (BSA).

          -  Have a combined total lesion severity score (TLSS) of ≥ 7 for the Target Lesion.

          -  Have a plaque elevation score ≥ 3 of (moderate) for the Target Lesion.

          -  The Target Lesion must have an area of at least 5 cm².

          -  Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at
             baseline for the overall disease severity.

        Exclusion Criteria:

          -  Patient has current diagnosis of other types of psoriasis other than stable plaque
             psoriasis (i.e. acute, guttate, erythrodermic, exfoliative or pustular psoriasis) or
             has psoriasis of any kind of the face or scalp that will require active treatment
             during the study. Nonprescription antipsoriatic shampoos will be allowed during the
             study when applied solely to the scalp.

          -  Patient has a history of psoriasis that has been unresponsive to topical
             corticosteroid therapy.

          -  In the Investigator's opinion, the patient has other dermatological conditions, such
             as atopic or contact dermatitis, that may interfere with the clinical assessments of
             the signs and symptoms of psoriasis.

          -  Patient has a history of allergy or sensitivity to corticosteroids or history of any
             drug hypersensitivity or intolerance which, in the opinion of the Investigator, would
             compromise the safety of the patient or the results of the study.

          -  Patient has been treated within 12 weeks (or five half lives, whichever is less) prior
             to the first dose of study drug with any biological therapies for psoriasis.

          -  Patient has received any systemic steroids within 4 weeks of the first dose of the
             study drug. The use of inhaled or intranasal corticosteroids is acceptable as long as
             usage has been stable for at least 2 weeks prior to the first dose of study drug and
             will be continued during the study.

          -  Patients who have used any topical antipsoriatic agents of any kind or any topical
             corticosteroids for any reason within 2 weeks prior to first use of study drug.
             Nonprescription antipsoriatic shampoos used only on the scalp will be allowed during
             the study.

          -  Receipt of any drug as part of a research study within 30 days prior to first dosing.